Solana (HSDT) vs Neuraxis (NRXS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Neuraxis (NRXS) has outperformed Solana (HSDT) over the past year, gaining 116.3% versus a loss of 86.8%. Solana is the larger company by market cap ($155.6 million vs $87.0 million), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HSDT | NRXS |
|---|---|---|
| Share price | $2.39 | $6.93 |
| Market cap | $155.60M | $87.03M |
| 1-day change | +0.42% | +2.36% |
| YTD return | -17.65% | +49.12% |
| 1-year return | -86.80% | +116.29% |
| 5-year return | -100.00% | — |
| P/E ratio (TTM) | 0.04 | — |
| EPS (TTM) | $53.74 | $-0.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $16.81 | $9.33 |
| 52-week low | $1.19 | $2.21 |
| Distance from 52-week high | -85.78% | -25.72% |
| Analyst consensus | none | none |
| Avg. price target upside | +46.44% | +58.73% |
| Average volume | 351.13K | 107.27K |
| Shares outstanding | 65.10M | 12.56M |
| Employees | 21 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRXS has outperformed HSDT by 203.1 percentage points over the past year.
About Solana
HSDT stock →Solana Company operates as a listed digital asset treasury. The company enhances Solana tokens per share on the commercially viable blockchain for decentralized finance and consumer applications.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 21 employees
About Neuraxis
NRXS stock →NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms.
Health Care · Biotechnology: Electromedical & Electrotherapeutic Apparatus · 24 employees
HSDT vs NRXS FAQ
Which is bigger, Solana or Neuraxis?
Solana (HSDT) is larger, with a market capitalization of $155.60M compared with $87.03M for Neuraxis (NRXS).
Which stock has performed better over the past year, HSDT or NRXS?
NRXS returned +116.29% over the past 12 months, compared with -86.80% for HSDT (price return, excluding dividends). Past performance does not predict future results.
Are Solana and Neuraxis in the same industry?
Yes. Both are classified in the Biotechnology: Electromedical & Electrotherapeutic Apparatus industry within the Health Care sector.